Home » Topics » Disease categories and therapies » Respiratory

Respiratory
RSS

Yamanouchi engages in NK antagonist research

March 6, 1998

U.K. market introduction for Singulair

March 5, 1998

Distribution and marketing of terfenadine-containing products discontinued in U.S.

March 4, 1998

FDA okays labeling change for Pulmozyme

March 3, 1998

Neuropeptide Y Y2 agonists prepared at Peptech/CRC

March 3, 1998

Milestone reached in Genome Therapeutics/Schering-Plough alliance

Feb. 27, 1998

Fujisawa develops new inhibitors of NO production

Feb. 27, 1998

Ariflo possesses potent antiinflammatory activity, without GI side effects

Feb. 26, 1998

T-440: a new antiasthma drug candidate from Tanabe

Feb. 26, 1998

Animal study indicates efficacy of oral PAF antagonist in allergic rhinitis

Feb. 26, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 11, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...